European Biotechnology Magazine

ADVERTISEMENT

ADVERTISEMENT

gold lingot

Venture Capital

Forbion raises record-breaking €2.3B to back 30 biotechs

Dutch life sciences investor Forbion has raised €2.3 billion across two new funds to finance about 30 biotech companies, setting a fundraising record for the firm. more ➔

Marian Kupculak, Co-Founder and CSO of Sensible Biotechnologies, and Miroslav “Miro” Gasparek, Co-Founder and CEO

Sensible secures $47M to rethink mRNA manufacturing

Oxford-based Sensible Biotechnologies has secured a $47 million (€42 million) financing package to scale a platform that makes mRNA in living cells, targeting manufacturing costs and unwanted immune … more ➔

ADVERTISEMENT

Andrew Lightfoot

RougeTx launches with $58M to tackle rare bleeding disorder

Dutch biotech RougeTx has launched with a $58 million (€52 million) series A to take its lead drug RTX-001 toward first-in-human testing in hereditary hemorrhagic telangiectasia (HHT). The round was … more ➔

A blue orange sliced into two halves with aesthetic blue background

Genmab and AbbVie’s bispecific antibody halves progression-or-death risk in lymphoma trial

Genmab and AbbVie’s bispecific antibody epcoritamab, added to R-CHOP chemoimmunotherapy, cut the risk of progression or death by 51% in a Phase 3 trial in newly diagnosed diffuse large B-cell lymphoma … more ➔

AI biotech illustration

Venture Capital

“AI biotech” is no longer a useful category for investors

AI has transformed drug discovery, but the “AI biotech” label has become increasingly misleading. Kurma Partners proposes an investment framework that distinguishes three fundamentally different … more ➔

European Biotechnology

1 / 4

EBM 3.2026 Autumn_cover

The autumn issue of European Biotechnology magazine asks what happens when biotech leaves Earth. Our cover story explores how microgravity could help researchers study disease, improve drug formulations … more ➔

Get a free sample copy | Abo

2 / 4

The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies. This issue features a list of eight venture capital firms to watch in 2026. … more ➔

Get a free sample copy | Abo

3 / 4

The Spring 2026 issue of European Biotechnology Magazine presents a list of start-ups to watch in 2026 and explores other fascinating topics such as: Can biotechnology finally fix infertility? Can … more ➔

Get a free sample copy | Abo

4 / 4

EB425_Cover

Europe is losing much of its expertise in deep tech and life sciences to the US. To prevent another generation of innovation from being lost, Europe must close the funding gaps. more ➔

Get a free sample copy | Abo

ADVERTISEMENT

© AI

NEWSLETTER

Stay up to date with the biotech industry!

Once a week, european-biotechnology.com brings you up to date on the latest developments in the biotech industry. In our free newsletter, you will find the latest news from business, research and politics, as well as lots of useful information and job vacancies.

Subscribe to our free newsletter!Subscribe here

WhiteLab Genomics team

WhiteLab secures $26M to expand AI-designed gene delivery assets

France’s WhiteLab Genomics has raised $26 million (€23 million) in Series B financing to expand experimental validation of its AI-designed gene delivery technologies and build a portfolio of assets … more ➔

funding spending

Entrepreneurship

Fundraising: Why relationships matter more than ever

If you ask founders what determines whether they raise capital, most will give you the same answer: great science, compelling clinical data, a large market opportunity and a sensible valuation. For a … more ➔

ADVERTISEMENT

Sponsored Publications

1 / 4

Justyna Adamczyk,
Associate VP Integrated MS&T at Rezon Bio

Designing biologics for commercial success

Justyna Adamczyk, Associate VP Integrated MS&T at Rezon Bio, discusses why integrating development and manufacturing strategies is key to improving late-stage efficiency and commercialization rea … more ➔

2 / 4

Professor Jacob George, Chief Medical and Scientific Officer at the MHRA presenting his keynote speech at Phacilitate Advanced Therapies Europe, 2026

Cell & Gene Therapy

Europe’s CGT advantage at risk

Industry leaders at Advanced Therapies Europe 2026 warned that Europe must tackle barriers across commercialisation, regulation, reimbursement, manufacturing and patient access to retain its global … more ➔

3 / 4

Ute Kilger

intellectual property

G 1/25: Form over function and how expensive is it?

In proceedings before the European Patent Office (EPO), applicants are required to „adapt“ the description to the claims of a patent application once the claims are deemed allowable. The adaptation … more ➔

4 / 4

Ponchi Kantt-Neaz, Global Executive Business Director 3PBIOVIAN

Commercial Strategy

3PBIOVIAN appoints Ponchi Kantt-Neaz as Global Executive Business Director

The appointment of Ponchi marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence … more ➔

APPOINTMENTS

all appointments

EB.com_Qiagen_CEO_Jonathan_Pratt

New CEO took over the reins

At the beginning of September, Jonathan M. Pratt succeeded Thierry Bernard as CEO of Qiagen N.V. Bernard had led the biotech pioneer …
more ➔

Samanta Cimitan

Samanta Cimitan to (re)join Lonza from Celonic

Samanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President and a member of the Extended Executive Committee …
more ➔

eb.com_Teresa Nunes CMO_EpilepsyGTX

Clinical Development Expert has started

London-based EpilepsyGTx has appointed Dr Teresa Nunes as Chief Medical Officer (CMO) to support the continued development of the company’s …
more ➔

tk.de_Andreas_Pahl_Heidelberg_Pharma

Simris Group AB

Simris Group AB

ADC expert appointed as CEO

Professor Andreas Pahl took over as Chief Executive Officer of Simris Biologics GmbH in mid-July. The subsidiary of Swedish Simris …
more ➔

The fibrotic signaling of overexpressed Claudin-1 can be inhibited with the Alentis antibody which helps diminishing collagen bundles in extracellular matrix tissue

Alentis Therapeutics

Fibrotic tissues

CSL backs Swiss Alentis’ claudin-1 bet with up to $1.6bn deal

Australian biopharma company CSL has entered an exclusive global partnership with Basel-based Alentis Therapeutics to co-develop and co-commercialize lixudebart, an investigational antibody targeting … more ➔

ADVERTISEMENT

genmab office

Genmab’s Phase 2 data strengthens case for $1.8B ProfoundBio bet

Genmab’s rinatabart sesutecan (Rina-S) delivered durable responses in a Phase 2 trial in platinum-resistant ovarian cancer, providing encouraging validation for the centerpiece of its $1.8 billion … more ➔

Suzhou, Jiangsu, China

Novartis bets up to $7.8B on Abogen’s mRNA autoimmune therapy

Novartis is paying China’s Abogen Biosciences $575 million (€512 million) upfront for global rights to ABO2203, an experimental treatment that uses mRNA to make a B-cell-depleting drug inside the … more ➔

newsletter_link

EVENT

16x9

October 12 @ 11:00 - 16:00in Basel, Switzerland

Bioprocess Day, Science Connected: From R&D to Manufacturing

Bioprocess Day in Basel: an open house for everyone interested in upstream bioprocessing. Date and time: 12 October 2026, from 11 a.m. - 4 p.m, with no fixed agenda so you can join us whenever it fits your schedule. Registration is free of charge. ➔